MYCBPAP

Across TCGA pan-cancer cohorts, MYCBPAP Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MYCBPAP data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MYCBPAP Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated MYCBPAP expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, STAD, and HNSC are the cancer types where MYCBPAP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.971	0.622	.006	22	view →
STAD	OS	Median	All	0.315	0.672	.011	12	view →
HNSC	OS	Median	II,III,IV	0.196	0.710	.023	9	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	9	view →
SARC	DFS	Median	All	0.006	0.611	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MYCBPAP–UCEC (DFS)

Open the UCEC breakdown →